RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy. Sometimes the transplanted cells are rejected by the body's tissues. Peripheral stem cell transplantation with the person's own stem cells followed by donor peripheral stem cell transplantation may prevent this from happening.

PURPOSE: Phase II trial to study the effectiveness of combining chemotherapy with autologous peripheral stem cell transplantation and donor peripheral stem cell transplantation in treating patients who have multiple myeloma.

Condition	Treatment or Intervention	Phase
refractory plasma cell neoplasm stage I multiple myeloma stage II multiple myeloma stage III multiple myeloma	Drug: cyclophosphamide  Drug: cyclosporine  Drug: fludarabine  Drug: melphalan  Drug: sargramostim  Procedure: biological response modifier therapy  Procedure: bone marrow ablation with stem cell support  Procedure: chemotherapy  Procedure: colony-stimulating factor therapy  Procedure: cytokine therapy  Procedure: graft versus host disease prophylaxis/therapy  Procedure: peripheral blood stem cell transplantation  Procedure: supportive care/therapy	Phase II

Further Study Details: 

OBJECTIVES:

• Determine the incidence of early mortality in patients with multiple myeloma treated with melphalan and autologous peripheral blood stem cell (PBSC) transplantation followed by fludarabine, cyclophosphamide, and allogeneic PBSC transplantation.
• Determine the incidence of early allogeneic graft failure (before day 100 after allogeneic PBSC transplantation) and the incidence of severe acute graft-versus-host disease (GVHD) in patients treated with this regimen.
• Determine the toxicity of this regimen in these patients.
• Determine the overall and disease-free survival of patients treated with this regimen.
• Correlate changes in the T-cell population with clinical outcome, such as survival, in patients treated with this regimen.
• Correlate changes in the T-cell population with the incidence of GVHD, use of immunosuppressive agents, and effects of fludarabine in patients treated with this regimen.
• Determine the degree of chimerism after allogeneic PBSC transplantation and the time course over which it is established in patients treated with this regimen.

OUTLINE: This is a multicenter study.

Patients receive melphalan IV over 15 minutes on day -1. Autologous peripheral blood stem cells (PBSCs) are reinfused on day 0. Patients also receive sargramostim (GM-CSF) subcutaneously (SC) or IV over at least 30 minutes daily beginning on day 1 and continuing until blood counts recover. Beginning 100-182 days after autologous PBSC transplantation, patients receive fludarabine IV over 30 minutes on days -6 to -2 and cyclophosphamide IV over 1-2 hours on days -3 and -2. Allogeneic PBSCs are infused on day 0. Patients may receive a second allogeneic PBSC infusion on day 1. Patients also receive GM-CSF SC or IV over at least 30 minutes daily beginning on day 1 and continuing until blood counts recover. Cyclosporine is administered IV or orally twice daily as graft-versus-host disease (GVHD) prophylaxis, beginning on day -1 and continuing until day 60, followed by a taper in the absence of GVHD.

Patients are followed for 5 years.

PROJECTED ACCRUAL: A total 19-46 patients will be accrued for this study within 3 years.

Ages Eligible for Study:  18 Years   -   70 Years,  Genders Eligible for Study:  Both

Criteria

DISEASE CHARACTERISTICS:

• Diagnosis of multiple myeloma meeting 1 of the following criteria:
• Bone marrow plasmacytosis with at least 10% plasma cells
• Sheets of plasma cells
• Biopsy-proven plasmacytoma
• Meets at least 1 of the following criteria:
• Presence of myeloma (M)-protein in the serum
• Presence of M-protein in the urine
• Radiographic evidence of osteolytic lesions
• Generalized osteoporosis allowed if at least 20% plasma cells in bone marrow
• No non-secretory myeloma
• Prior M-protein in serum or urine allowed provided patient is now in complete remission
• Must be receiving conventional-dose chemotherapy as initial therapy or as salvage therapy
• Must have HLA-A, -B, and -DR genotypically identical sibling donor

PATIENT CHARACTERISTICS: Age:

• 18 to 70

Performance status:

• ECOG 0-2

Life expectancy:

• Not specified

Hematopoietic:

• See Disease Characteristics

Hepatic:

• AST no greater than 3 times upper limit of normal
• Bilirubin less than 2.0 mg/dL

Renal:

• Not specified

Cardiovascular:

• LVEF greater than 40% at rest if symptomatic cardiac disease is present

Pulmonary:

• DLCO greater than 50% of predicted (corrected for hemoglobin) if symptomatic pulmonary disease is present

Other:

• Not pregnant or nursing
• Fertile patients must use effective contraception

PRIOR CONCURRENT THERAPY: Biologic therapy:

• No prior autologous or allogeneic peripheral blood stem cell or bone marrow transplantation

Chemotherapy:

• See Disease Characteristics
• More than 28 days since prior chemotherapy (including primary chemotherapy for hematopoietic stem cell collection)
• No other concurrent cytotoxic chemotherapy between autologous and allogeneic transplantation

Endocrine therapy:

• Prior dexamethasone or other corticosteroids allowed
• Concurrent corticosteroids between autologous and allogeneic transplantation allowed

Radiotherapy:

• Concurrent radiotherapy between autologous and allogeneic transplantation allowed

Surgery:

• Not specified

Florida
      Baptist Cancer Institute - Jacksonville, Jacksonville,  Florida,  32207-8554,  United States
      Mayo Clinic - Jacksonville, Jacksonville,  Florida,  32224,  United States
Massachusetts
      Beth Israel Deaconess Medical Center, Boston,  Massachusetts,  02215,  United States
      Cancer Center at Tufts - New England Medical Center, Boston,  Massachusetts,  02111,  United States
Minnesota
      Mayo Clinic Cancer Center, Rochester,  Minnesota,  55905,  United States
New Jersey
      Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School, New Brunswick,  New Jersey,  08903,  United States
      CCOP - Northern New Jersey, Hackensack,  New Jersey,  07601,  United States
New York
      MBCCOP-Our Lady of Mercy Cancer Center, Bronx,  New York,  10466,  United States
Ohio
      Ireland Cancer Center at University Hospitals of Cleveland and Case Western Reserve University, Cleveland,  Ohio,  44106-5065,  United States
      MetroHealth's Cancer Care Center at MetroHealth Medical Center, Cleveland,  Ohio,  44109,  United States
Pennsylvania
      Abramson Cancer Center at the University of Pennsylvania, Philadelphia,  Pennsylvania,  19104,  United States
      Penn State Cancer Institute at Milton S. Hershey Medical Center, Hershey,  Pennsylvania,  17033-0850,  United States

Study chairs or principal investigators

Neal Flomenberg, MD,  Study Chair,  Kimmel Cancer Center (KCC)   

Study ID Numbers:  CDR0000068551; ECOG-E4A98; NCT00014508
Record last reviewed:  February 2005
Last Updated:  February 9, 2005
Record first received:  April 10, 2001
ClinicalTrials.gov Identifier:  NCT00014508
Health Authority: United States: Federal Government
ClinicalTrials.gov processed this record on 2005-04-08